Simultaneous In Vitro Profiling of Anticancer Efficacy and Toxicity
Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...
Continue Reading
Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...
Continue Reading
Bispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...
Continue Reading
PARP1 plays a central role in DNA repair and is a well-established target across multiple cancer types. Understanding the vulnerabilities...
Continue Reading
Targeted lipid nanoparticles (tLNPs) are advancing in vivo CAR-T therapies by facilitating the in situ generation of CAR-T effectors, offering...
Continue Reading
Neutrophilic asthma remains one of the most challenging forms of asthma to study, with limited preclinical models available to support...
Continue Reading
Metabolic dysfunction-associated alcohol-related liver disease (MetALD) presents unique challenges for preclinical drug development, requiring models that capture the combined effects...
Continue Reading
Metabolic dysfunction-associated steatohepatitis (MASH) remains a significant global health challenge, driven by a complex interplay of lipid dysregulation, inflammation, and...
Continue Reading
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...
Continue Reading
Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...
Continue Reading